STOCK TITAN

Neurocrine Biosciences, Inc. - NBIX STOCK NEWS

Welcome to our dedicated news page for Neurocrine Biosciences (Ticker: NBIX), a resource for investors and traders seeking the latest updates and insights on Neurocrine Biosciences.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Neurocrine Biosciences's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Neurocrine Biosciences's position in the market.

Rhea-AI Summary
Neurocrine Biosciences will present new analysis of Phase 2 data for crinecerfont in adolescent patients with CAH, suggesting potential for greater response to treatment with higher baseline hormone levels. No correlation found between baseline GC dose and treatment response. Crinecerfont was generally well tolerated in adolescents with no serious adverse events. Results consistent with Phase 2 study in adults. Phase 3 CAHtalyst Pediatric Study results to be announced in early Q4 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.11%
Tags
none
-
Rhea-AI Summary
Neurocrine Biosciences' NDA for INGREZZA oral granules accepted by FDA with a target action date of April 30, 2024
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.45%
Tags
-
Rhea-AI Summary
Neurocrine Biosciences' Phase 3 CAHtalyst study shows positive results for crinecerfont in treating CAH
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.8%
Tags
Rhea-AI Summary
Neurocrine Biosciences initiates Phase 1 study for investigational compound NBI-1117570
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.34%
Tags
-
Rhea-AI Summary
Neurocrine Biosciences to present at two upcoming investor conferences in September
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.6%
Tags
conferences
-
Rhea-AI Summary
Neurocrine Biosciences presents new data on INGREZZA for Huntington's disease at MDS Congress
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.6%
Tags
none
Rhea-AI Summary
Neurocrine Biosciences receives FDA approval for INGREZZA capsules for the treatment of chorea associated with Huntington's disease, offering a simple dosing regimen. Key clinical trial outcomes show significant improvement in chorea severity compared to placebo. Important safety information is included in the prescribing information. INBRACE Support Program is available for patients prescribed INGREZZA.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Neurocrine Biosciences, Inc. (NBIX) announced a 26% year-over-year growth in INGREZZA® (valbenazine) net product sales for the second quarter, reaching $440 million. The company also raised 2023 net product sales guidance to $1.77 - $1.82 billion, reflecting the significant benefit the medicine provides to patients with tardive dyskinesia. The financial results revealed a record number of new patients receiving therapy, with GAAP net income and earnings per share of $96 million and $0.95, respectively.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.52%
Tags
-
Rhea-AI Summary
Neurocrine Biosciences has appointed Christine A. Poon, a business leader with extensive experience in the pharmaceutical industry, to its Board of Directors. Ms. Poon has a 30-year career in the healthcare industry, including serving as Vice Chairman and Member of the Board of Directors of Johnson & Johnson. She brings a wealth of industry experience to Neurocrine's Board of Directors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.98%
Tags
management
Rhea-AI Summary
Neurocrine Biosciences, Inc. has scheduled its second quarter 2023 financial results conference call and webcast for August 1, 2023 at 5:00 a.m. PT / 8:00 a.m. ET. The press release will be issued at 4:00 a.m. PT / 7:00 a.m. ET. Investors can access the webcast on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.98%
Tags
Neurocrine Biosciences, Inc.

Nasdaq:NBIX

NBIX Rankings

NBIX Stock Data

13.54B
98.22M
1%
94.39%
2.44%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
US
San Diego

About NBIX

neurocrine biosciences, inc of san diego is a product based biopharmaceutical company focusing on the development and commercialization of innovative pharmaceutical products to treat unmet medical needs. the company's research and development efforts are focused on neurological and endocrine diseases and disorders. our product candidates address some of the largest pharmaceutical markets in the world including endometriosis, irritable bowel syndrome, anxiety, depression, pain, diabetes, insomnia, and other neurological and endocrine related diseases and disorders